– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 –
– Extended cash runway into 2H24 –
https://www.biospace.com/article/releases/update-longeveron-provides-corporate-update-and-announces-2023-strategic-priorities-and-anticipated-milestones/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.